

# Human immunoglobulin $C_{\lambda 6}$ gene encodes the $\text{Kern}^+\text{Oz}^-$ $\lambda$ chain and $C_{\lambda 4}$ and $C_{\lambda 5}$ are pseudogenes

(isotypes/allotypes/Bence Jones proteins/constant region genes)

P. DARIAVACH, G. LEFRANC, AND M.-P. LEFRANC

Laboratoire d'Immunogénétique, Centre National de la Recherche Scientifique Unité Associée 1191, Génétique Moléculaire, Université des Sciences et Techniques du Languedoc, Place E. Bataillon, 34060 Montpellier Cedex, France

Communicated by C. Milstein, August 3, 1987 (received for review May 28, 1987)

**ABSTRACT** Six nonallelic immunoglobulin  $\lambda$  constant region genes have been previously characterized on a 40-kilobase stretch of DNA. The nucleotide sequences of the three upstream genes of this cluster ( $C_{\lambda 1}$ ,  $C_{\lambda 2}$ ,  $C_{\lambda 3}$ ) have been determined by other workers and shown to encode, respectively, the isotypic Mcg,  $\text{Kern}^-\text{Oz}^-$ , and  $\text{Kern}^-\text{Oz}^+$  constant region of the  $\lambda$  chains. In this paper, we report the sequence of the three downstream genes of this cluster and show that two of them ( $C_{\lambda 4}$  and  $C_{\lambda 5}$ ) are pseudogenes. However,  $C_{\lambda 6}$  encodes a  $\text{Kern}^+\text{Oz}^-$  chain and corresponds to the fourth isotype described among the  $\lambda$  proteins sequenced so far. A potentially active  $J_{\lambda}$  (joining) segment, with the canonical heptamer and nonamer sequences for rearrangement, is located 1.5 kilobases upstream of  $C_{\lambda 6}$ . The amino acid sequence encoded by the  $C_{\lambda 6}$  gene is compared with the constant region sequences of various monoclonal Bence Jones  $\lambda$  proteins. Allotypic and isotypic differences confirm the polymorphism and complexity of the human  $C_{\lambda}$  locus.

In humans, the constant (C) region of the immunoglobulin  $\lambda$  light chains consists of at least four nonallelic or isotypic forms that differ by limited amino acid substitutions to produce the serological markers Kern (Ke) (1, 2), Oz (3-5), and Mcg (6, 7). Several additional substitutions have been described (8-16), but it is unknown whether these represent allelic variants or distinct isotypes. The human immunoglobulin  $\lambda$  light chain genes have been mapped to chromosome 22 (17) at band q11 (18, 19), and six nonallelic  $\lambda$  C region genes ( $C_{\lambda 1}$  to  $C_{\lambda 6}$ ) have been characterized on a 40-kilobase (kb) stretch of DNA (20). The number of  $C_{\lambda}$  genes varies between six and nine per haploid genome (21). These variations were detected by restriction fragment length polymorphism (21) and seem to have arisen from unequal meiotic crossing-over with a duplication of the  $C_{\lambda 2}$  and  $C_{\lambda 3}$  genes. Moreover, three additional  $C_{\lambda}$ -like genes have been recently identified, which map on different stretches of DNA and are nonallelic (22). One of these is a pseudogene, whereas the two others encode a putative  $\lambda$  chain C region whose sequence differs from that of the  $\lambda$  chains described so far.

Only three  $C_{\lambda}$  genes ( $C_{\lambda 1}$ ,  $C_{\lambda 2}$ , and  $C_{\lambda 3}$ ) belonging to the cluster described by Hieter have been sequenced (20), and they have been shown to encode, respectively, the Mcg,  $\text{Kern}^-\text{Oz}^-$ , and  $\text{Kern}^-\text{Oz}^+$  C region of the  $\lambda$  chains. In this paper, we report the sequences\* of the three genes located downstream in this cluster and show that two of them ( $C_{\lambda 4}$  and  $C_{\lambda 5}$ ) are pseudogenes, whereas  $C_{\lambda 6}$  encodes a  $\text{Kern}^+\text{Oz}^-$  chain, the fourth isotype described among the proteins sequenced so far. This  $C_{\lambda 6}$  gene has a potentially active  $J_{\lambda 6}$  joining region, with the canonical heptamer and nonamer sequences for rearrangement, 1.5 kb upstream of the coding C region.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

## MATERIALS AND METHODS

**Construction of a Phage Library from LY67 DNA.** DNA prepared from LY67 cells (a  $\lambda$ -producing Burkitt's lymphoma) (23) was partially digested with *Mbo* I. Restriction fragments 15-20 kb long were ligated into *Bam*HI-digested DNA of phage  $\lambda$ 2001 (24) and packaged *in vitro*. Recombinant phages were screened by the *in situ* plaque hybridization procedure (25).

**Probes.** A genomic clone (Chr 22 $\lambda$ 5) in  $\lambda$ gt- $\lambda$ WES (26) was kindly provided by T. H. Rabbitts (Medical Research Council, Cambridge, England). This clone contains an 8.0-kb *Eco*RI fragment that includes the known nonallelic  $\text{Kern}^-\text{Oz}^-$  ( $C_{\lambda 2}$ ) and  $\text{Kern}^-\text{Oz}^+$  ( $C_{\lambda 3}$ ) genes and the flanking sequences (20). We subcloned a 700-base-pair (bp) *Bgl* II-*Eco*RI fragment containing only the  $\text{Kern}^-\text{Oz}^-$   $C_{\lambda 3}$  gene (Fig. 1), and this  $C_{\lambda}$  probe cross-hybridizes with all the other  $C_{\lambda}$ -like genes (20). It was radioactively labeled with [ $\alpha$ - $^{32}$ P]dCTP by nick-translation (27) and was used to screen the LY67 phage library.

**Subcloning and Sequencing Strategies.** One clone, LY67  $C_{\lambda 3-6}$  (Fig. 1), was shown to contain  $C_{\lambda 3}$  to  $C_{\lambda 6}$ . Appropriate subclones were made in pUC vectors (29). Nucleotide sequence analysis was carried out by dideoxy chain-termination procedures (30) in M13 vectors (31) by deploying exonuclease III-nuclease S1 methods (32) or directed sequencing using known restriction enzyme sites.

**Oligonucleotide Synthesis and Hybridization.** A 19-mer oligonucleotide 5' GTGTTTCGGCGGAGGGACCA 3' corresponding to part of the  $J_{\lambda 3}$  gene segment sequence (this paper and ref. 28) was synthesized, radiolabeled, and hybridized to the LY67  $C_{\lambda 3-6}$  clone to search for other  $J_{\lambda}$  segments. Low-stringency washes were carried out at room temperature.

## RESULTS

**Rearrangement of a  $V_{\lambda III}$  Subgroup Gene to  $J_{\lambda 3}$  in the LY67 Cell Line.** One clone (LY67  $C_{\lambda 3-6}$ ) containing a 18-kb piece of genomic DNA was isolated and characterized. A restriction map of this clone is shown in Fig. 1. Comparison of this map with one previously published (20) suggested that this clone contains four  $C_{\lambda}$  genes, namely  $C_{\lambda 3}$  to  $C_{\lambda 6}$ . The sequence of the 5' end of the LY67  $C_{\lambda 3-6}$  clone shows that a  $V_{\lambda}$  gene rearrangement has occurred, joining this gene to the  $J_{\lambda 3}$  gene segment, which is located 1.5 kb upstream of  $C_{\lambda 3}$  (28). Fig. 2A shows the partial nucleotide sequence of the rearranged  $V_{\lambda}$  in LY67 and that of a  $V_{\lambda}$  gene assigned to the  $V_{\lambda III}$  subgroup and isolated from the Burkitt lymphoma cell line PA682 (28).

Abbreviations: C, constant; J, joining; V, variable; Ke, Kern.

\*The sequences reported in this paper are being deposited in the EMBL/GenBank data base (Bolt, Beranek, and Newman Laboratories, Cambridge, MA, and Eur. Mol. Biol. Lab., Heidelberg) [accession nos. J03009 ( $C_{\lambda 4}$ ), J03010 ( $C_{\lambda 5}$ ), and J03011 ( $C_{\lambda 6}$ )].




FIG. 1. (A) Restriction map of LY67 C<sub>λ</sub>3-6 clone. (B) Sequencing strategy. B, *Bam*HI; Bg, *Bgl* II; H, *Hind*III; R, *Eco*RI; S, *Sst* I. Of the *Pst* I sites (P), only the one used for subcloning the fragment containing the C<sub>λ</sub>6 gene is indicated. The rearrangement V-J<sub>λ</sub>3 is indicated by an arrow (V, variable region). An asterisk shows the location of a polymorphic *Bam*HI site present in PA682 DNA (28) but absent from our LY67 clone.

The deduced amino acid sequence of the rearranged V gene of LY67 is also compared to the V region of the protein DEL of the subgroup V<sub>λ</sub>III (33, 34). A 75% sequence identity indicates that the V<sub>λ</sub> gene rearranged in LY67 is a member of the V<sub>λ</sub>III subgroup gene family, and this is in agreement with the detection of a transcript hybridizing to a V<sub>λ</sub>III probe in the

LY67 cell line (28). The J<sub>λ</sub>3 segment of the LY67 C<sub>λ</sub>3-6 clone, compared to the J<sub>λ</sub>3 segment rearranged in PA682, shows two nucleotide differences (one of them resulting in a valine/leucine amino acid substitution) that may be due to allelic polymorphism. Two other nucleotide differences are observed at the V-J junction and are probably explained by a flexibility in the mechanism by which junctions occur (35, 36).

**C<sub>λ</sub>6 Encodes a Ke<sup>+</sup>Oz<sup>-</sup> Chain.** Fig. 2B shows the nucleotide sequence of the C<sub>λ</sub>6 gene and the encoded amino acid sequence (106 residues). The residues Ala, Ser, and Thr, found, respectively, at codons 6, 8, and 57 (positions 112, 114, and 163 according to ref. 34) indicate that C<sub>λ</sub>6 encodes a Mcg<sup>-</sup> protein. Arg (codon 83, position 190) corresponds to the Oz<sup>-</sup> marker, whereas Gly (codon 46, position 152) characterizes the Ke<sup>+</sup> marker. Therefore the C<sub>λ</sub>6 gene encodes the fourth isotype Ke<sup>+</sup>Oz<sup>-</sup>.

**J<sub>λ</sub>6 Segment Is 1.5 kb Upstream of C<sub>λ</sub>6.** Only the J<sub>λ</sub>1 (22) and J<sub>λ</sub>3 segments (ref. 28 and this paper) have been characterized; they have been localized in genomic DNAs at 1.5 kb upstream of the respective C<sub>λ</sub> coding regions. We therefore used an oligonucleotide corresponding to the J<sub>λ</sub>3 sequence (see *Materials and Methods*) to search for homologous J<sub>λ</sub> segments in the LY67 C<sub>λ</sub>3-6 clone. As expected, a strong signal was obtained for the J<sub>λ</sub>3-containing fragments, whereas a weaker signal allowed us to detect the J<sub>λ</sub>6 segment in a *Sac* I-*Bgl* II fragment upstream of C<sub>λ</sub>6. The sequence of this J<sub>λ</sub>6 segment (Fig. 2C) showed that it encodes 12 amino acids (among them the characteristic Phe-Gly-Xaa-Gly residues) and that it also possesses the canonical heptamer and nonamer sequences essential to V-J rearrangement (37, 38). No signal corresponding to the putative J<sub>λ</sub>4 and J<sub>λ</sub>5 segments could be detected in the LY67 C<sub>λ</sub>3-6 clone by using either the oligonucleotides (J<sub>λ</sub>3 probe) or the genomic *Sac* I-*Bgl* II fragment (J<sub>λ</sub>6 probe), indicating that if these segments exist their homology is too weak to be detected in our conditions of hybridization. Since the J<sub>λ</sub>3 and J<sub>λ</sub>6 gene segments are 1.5 kb upstream of their respective coding regions, we subcloned fragments located, respectively, at about the same distance upstream of C<sub>λ</sub>4 and C<sub>λ</sub>5. Although in both cases, we detected some conserved heptamer sequences, we did not




FIG. 2. Nucleotide and amino acid sequences. (A) Partial sequence of the LY67 V<sub>λ</sub>-J<sub>λ</sub>3 rearranged gene. (B) Sequence of the C<sub>λ</sub>6 gene. (C) Sequence alignment of J<sub>λ</sub>6 and J<sub>λ</sub>1 (22).




FIG. 3. Nucleotide sequence alignment of the human  $C_\lambda$  genes. Dots indicate identity with  $C_{\lambda 1}$ ; dashes indicate gaps.

find the characteristic Phe-Gly-Xaa-Gly residues or the expected splice site at a downstream position. It is possible that the heptamer sequences are attached to poorly conserved pseudo  $J_\lambda$  segments and we cannot exclude the possibility that the putative  $J_{\lambda 4}$  and  $J_{\lambda 5}$  are localized in

fragments that were not sequenced, upstream of the  $C_{\lambda 4}$  and  $C_{\lambda 5}$  genes.

**$C_{\lambda 4}$  and  $C_{\lambda 5}$  Are Pseudogenes.** Nucleotide sequences and the encoded amino acid sequences of  $C_{\lambda 4}$  and  $C_{\lambda 5}$  are shown in Figs. 3 and 4. Both genes are pseudogenes; the third codon of  $C_{\lambda 4}$  is a stop codon, and  $C_{\lambda 4}$  displays three deletions. The first deletion of 9 bp spans codons 5 to 7 and the other two deletions excise codons 21 and 64.  $C_{\lambda 5}$  has an 11-bp deletion (codons 41–44) resulting in a frameshift.




FIG. 4. Protein sequences derived from the human  $C_\lambda$  gene sequences. The standard one-letter symbols are used.

Table 1. Amino acid differences between the four nonallelic forms of the human  $C_\lambda$  regions

Isotype	Gene	Amino acid residue				
		112 (6)	114 (8)	152 (46)	163 (57)	190 (83)
Mcg <sup>+</sup> Ke <sup>+</sup> Oz <sup>-</sup>	$C_{\lambda 1}$	Asn	Thr	Gly	Lys	Arg
Mcg <sup>-</sup> Ke <sup>-</sup> Oz <sup>-</sup>	$C_{\lambda 2}$	Ala	Ser	Ser	Thr	Arg
Mcg <sup>-</sup> Ke <sup>-</sup> Oz <sup>+</sup>	$C_{\lambda 3}$	Ala	Ser	Ser	Thr	Lys
Mcg <sup>-</sup> Ke <sup>+</sup> Oz <sup>-</sup>	$C_{\lambda 6}$	Ala	Ser	Gly	Thr	Arg

Residue numbering is according to ref. 34; parentheses enclose numbering of the codons in the  $C_\lambda$  genes.




FIG. 5. Physical map of the human  $\lambda$  light chain C region.  $C_{\lambda 1}$ ,  $C_{\lambda 2}$ , and  $C_{\lambda 3}$  correspond, respectively, to the nonallelic Mcg,  $Ke^-Oz^-$ , and  $Ke^-Oz^+$  chains (ref. 20; see Table 1).  $C_{\lambda 4}$  and  $C_{\lambda 5}$  are pseudogenes ( $\psi$ ), whereas  $C_{\lambda 6}$  encodes a  $Ke^+Oz^-$  chain.  $J_{\lambda 1}$  (22),  $J_{\lambda 3}$  (ref. 28 and this paper), and  $J_{\lambda 6}$  (this paper) have been localized 1.5 kb upstream of  $C_{\lambda 1}$ ,  $C_{\lambda 3}$ , and  $C_{\lambda 6}$ , respectively.  $J_{\lambda 2}$  has not yet been localized in genomic DNA. No  $J_{\lambda}$  gene segment has so far been identified upstream of  $C_{\lambda 4}$  and  $C_{\lambda 5}$ .

DISCUSSION

In human  $\lambda$  chain C regions, the Mcg marker involves amino acid residues at positions 112, 114, and 163 (numbering according to ref. 34; Table 1) corresponding, respectively, to codons 6, 8, and 57 of the  $C_{\lambda}$  genes.  $Mcg^+$  proteins have residues Asn-112, Thr-114, and Lys-163, whereas  $Mcg^-$  proteins have residues Ala, Ser, and Thr, respectively, at these locations. However, the recently sequenced Mor protein is different from the other  $Mcg^-$  proteins by having Ala-163 instead of Thr-163 (16). The Ke and Oz markers occur at positions 152 and 190, respectively:  $Ke^+$  proteins have Gly-152 and  $Ke^-$  have Ser-152;  $Oz^+$  proteins have Lys-190 and  $Oz^-$ , Arg-190. These markers define four nonallelic forms of human  $\lambda$  chain C regions (Mcg,  $Ke^-Oz^-$ ,  $Ke^-Oz^+$ , and  $Ke^+Oz^-$ ), which are encoded, respectively, by the  $C_{\lambda 1}$ ,  $C_{\lambda 2}$ ,  $C_{\lambda 3}$  (20), and  $C_{\lambda 6}$  (this paper) genes (Fig. 5).

In Fig. 6, monoclonal Bence Jones proteins have been assigned as products of the  $C_{\lambda}$  genes 1, 2, 3, or 6 on the basis of the presence or absence of residues characteristic for the Mcg, Ke, and Oz markers. In most cases, there is complete concordance between the protein and the deduced amino acid sequence of the corresponding  $C_{\lambda}$  gene. However, other amino acid changes have been found in several proteins (Table 2 and Fig. 6). Since these substitutions have been noted only once, they could represent allotypic differences. However, it is not excluded that some of the proteins  $Ke^-Oz^-$  could be encoded by a  $C_{\lambda}$  gene resulting from the duplication of the  $C_{\lambda 2}$ - $C_{\lambda 3}$  region, as has been described in some individuals (21). In such cases these sequences should represent new isotypic differences due to the presence of several nonallelic copies of  $C_{\lambda 2}$  gene. Differences observed

Table 2. Sequence variations in the C region of human  $\lambda$  chains

Isotype	Common amino acid	Residue number	Variation amino acid	Protein	Ref.
Mcg	Lys	156	Glu	WEIR	8
$Ke^-Oz^-$	Lys	129	Glx	CH	9
			Arg	NIG68	10
			Ser	ATK	11
	Ala	143	Val	MZ	12, 13
			Ile	HIL	14
			Glu	SA	11
			Val	WAY	1
			Asn	MZ	12
			Arg	MOR	16
			Lys	ATK	11
Gln	195	Leu	NIG68	10	
		Lys	ATK	11	
$Ke^-Oz^+$	Asp	151	Glu	EV	15

Residue numbers according to Kabat *et al.* (34).

in the  $J_{\lambda 2}$  sequences (Fig. 6) might for the same reason be either allotypic or isotypic. Differences in the  $J_{\lambda 1}$  segment region might represent allotypic differences, although the presence of not yet identified other  $J_{\lambda 1}$  segments cannot be ruled out.

If we compare the deduced amino acid sequence of  $C_{\lambda 6}$  gene with two known  $Ke^+Oz^-$  proteins that have identical  $C_{\lambda}$  coding regions, SM (53) and Kern (52), the protein predicted for  $C_{\lambda 6}$  shows three differences: (i) lysine at position 145 (codon 39) instead of threonine, (ii) asparagine at position 156 (codon 50) instead of lysine, and (iii) alanine at position 212

Ref.	Gene	KERN	OZ	MCG	J $\lambda$		C $\lambda$															
					95	107	112	114	152	163	190	215										
(20, 22)	JA1-CA1	+	-	+	YVFGTGTQVTVLGGPKANPTVTLFPPSSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVAKAGVETTKPSKQSNKYAAS <sup>57</sup> YLSLTP <sup>83</sup> EQW <sup>83</sup> KSHRSYSCQVTHEGSTVERTVA <sup>106</sup> PT <sup>106</sup> CS <sup>106</sup>																	
(6)	MCG	+	-	+	F.....R.....																	
(8, 15)	WEIR	+	-	+	F.....R.....																	
(38)	MOT	+	-	+	V.....M.....																	
(20)	CA2	-	-	-	.....A.S.....																	
(39)	NEW	-	-	-	V.....G.....A.S.....																	
(40)	SH	-	-	-	VL.....G.....L.....A.S.....																	
(13, 42)	X	-	-	-	V.....G.....RL.....S.....A.S.....																	
(41)	HA	-	-	-	V.....G.....QL.....R.....A.S.....																	
(9)	CH	-	-	-	.....G.....L.....R.....A.S.....																	
(14)	HIL	-	-	-	ST.....G.....L.....A.S.....																	
(12, 13)	MZ	-	-	-	.....A.S.....																	
(10)	NIG68	-	-	-	.....A.S.....																	
(43)	BO	-	-	-	F.....G.....L.....R.....A.S.....																	
(44)	NEI	-	-	-	R.....G.....R.....S.....A.S.....																	
(33)	DEL	-	-	-	V.....G.....L.....R.....A.S.....																	
(45)	BAU	-	-	-	VI.....G.....L.....R.....A.S.....																	
(46)	TRO	-	-	-	VI.....G.....L.....R.....A.S.....																	
(16)	MOR	-	-	-	.....L.....S.....A.S.....																	
(This paper, 20)	JA3-CA3	-	+	-	.....G.....L.....A.S.....																	
(5)	OZ	-	+	-	.....A.S.....																	
(47)	SUT	-	+	-	W.....G.....L.....A.S.....																	
(48)	THO	-	+	-	W.....G.....L.....A.S.....																	
(49)	NEWM	-	+	-	R.....G.....L.....R.....A.S.....																	
(50)	VOR	-	+	-	P.....G.....L.....R.....A.S.....																	
(51)	cdNA EB4	-	+	-	G.....G.....L.....R.....A.S.....																	
(This paper, 52)	JA6-CA6	+	-	-	N.....S.....L.....A.S.....																	
(52)	KERN	+	-	-	AI.....G.....L.....S.....A.S.....																	
(53)	SM	+	-	-	.....A.S.....																	

FIG. 6. Sequences of C regions of human  $\lambda$  chains. The protein sequences encoded by the four "active"  $C_{\lambda}$  genes and associated  $J_{\lambda}$  gene segments are compared with the  $\lambda$  protein C regions. The numbering of the  $C_{\lambda}$  region amino acids is according to ref. 34—e.g., positions 169, 201, and 202 are excluded in the  $C_{\lambda}$  sequences for purposes of alignment with human  $C_{\lambda}$  chains. For an easier alignment, the  $J_{\lambda}$  and  $C_{\lambda}$  gene segments are considered as being spliced and a vertical line is drawn to indicate the V-J junction. The horizontal line in the SM sequence shows a deletion.

(codon 103) instead of threonine (Fig. 6). These differences may represent allotypic variations, although we cannot entirely exclude the possibility that these different  $\text{Ke}^+\text{Oz}^-$  sequences are encoded by nonallelic genes. More sequences of  $C_\lambda$  genes or  $\lambda$  proteins should help estimate the extent of the human  $\lambda$  chain polymorphism.

**Note Added in Proof.** The  $J_{\lambda 2}$  gene segment has recently been localized upstream of  $C_{\lambda 2}$  (54).

We are very grateful to Dr. T. H. Rabbitts for providing us with the LY67 cell line and Chr22 $\lambda$ 5 clone. We thank Dr. P. Fort for his collaboration, which was greatly appreciated. We also thank C. Aymard for synthesizing the oligonucleotide and Véronique Ramond for typing the manuscript. This work was supported by the Centre National de la Recherche Scientifique, the Association pour la Recherche sur le Cancer, the Fondation pour la Recherche Médicale, and the Ministère de la Recherche.

- Ponstingl, H., Hess, M. & Hilschmann, N. (1968) *Hoppe-Seyler's Z. Physiol. Chem.* **349**, 867–871.
- Hess, M., Hilschmann, N., Rivat, L., Rivat, C. & Ropartz, C. (1971) *Nature (London) New Biol.* **234**, 58–61.
- Ein, D. & Fahey, J. L. (1967) *Science* **156**, 947–950.
- Ein, D. (1968) *Proc. Natl. Acad. Sci. USA* **60**, 982–985.
- Appella, E. & Ein, D. (1967) *Proc. Natl. Acad. Sci. USA* **57**, 1449–1454.
- Fett, J. W. & Deutsch, H. F. (1974) *Biochemistry* **13**, 4102–4114.
- Fett, J. W. & Deutsch, H. F. (1975) *Immunochemistry* **12**, 643–652.
- Jabusch, J. R. & Deutsch, H. F. (1982) *Mol. Immunol.* **19**, 901–906.
- Okada, Y., Nozu, Y., Titani, K., Watanabe, S., Hara, H. & Kitagawa, M. (1972) *Immunochemistry* **9**, 207–210.
- Shinoda, T., Yoshimura, K., Kametani, F. & Isobe, T. (1983) *Biochem. Biophys. Res. Commun.* **117**, 587–592.
- Lieu, T. S., Deutsch, H. F. & Tischendoif, F. W. (1977) *Immunochemistry* **14**, 429–433.
- Milstein, C. (1967) *Nature (London)* **216**, 330–332.
- Milstein, C., Frangione, B. & Pink, J. R. L. (1967) *Cold Spring Harbor Symp. Quant. Biol.* **32**, 31–36.
- Lopez de Castro, J. A., Chiu, Y.-Y. H. & Poljak, R. J. (1978) *Biochemistry* **17**, 1718–1723.
- Fett, J. W. & Deutsch, H. F. (1976) *Immunochemistry* **13**, 149–155.
- Frangione, B., Moloshok, T., Prelli, F. & Solomon, A. (1985) *Proc. Natl. Acad. Sci. USA* **82**, 3415–3419.
- Erickson, J., Martinis, J. & Croce, C. M. (1981) *Nature (London)* **294**, 173–175.
- McBride, O. W., Hieter, P. A., Hollis, G. F., Swan, D., Otey, M. C. & Leder, P. (1982) *J. Exp. Med.* **155**, 1480–1490.
- de la Chapelle, A., Lenoir, G., Boué, J., Gallano, P., Huerre, C., Szajnert, M. F., Jeanpierre, M., Lalouel, J. M. & Kaplan, J. C. (1983) *Nucleic Acids Res.* **11**, 1133–1142.
- Hieter, P. A., Hollis, G. F., Korsmeyer, S. J., Waldmann, T. A. & Leder, P. (1981) *Nature (London)* **294**, 536–540.
- Taub, R. A., Hollis, G. F., Hieter, P. A., Korsmeyer, S., Waldmann, T. A. & Leder, P. (1983) *Nature (London)* **304**, 172–174.
- Chang, H., Dmitrovsky, E., Hieter, P. A., Mitchell, K., Leder, P., Turoczi, L., Kirsch, I. R. & Hollis, G. F. (1986) *J. Exp. Med.* **163**, 425–435.
- Lenoir, G. M., Preud'homme, J. L., Bernheim, A. & Berger, R. (1982) *Nature (London)* **298**, 474–476.
- Karn, J., Matthes, H. W. D., Gait, M. J. & Brenner, S. (1984) *Gene* **32**, 219–224.
- Benton, W. D. & Davis, R. W. (1977) *Science* **196**, 180–182.
- Rabbitts, T. H., Forster, A. & Matthews, J. (1983) *Mol. Biol. Med.* **1**, 11–19.
- Rigby, P. W. J., Dieckmann, M., Rhodes, C. & Berg, P. (1977) *J. Mol. Biol.* **113**, 237–251.
- Sun, L.-H. K., Croce, C. M. & Showe, L. C. (1985) *Nucleic Acids Res.* **13**, 4921–4934.
- Vieira, J. & Messing, J. (1982) *Gene* **19**, 259–268.
- Sanger, F., Nicklen, S. & Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 5463–5467.
- Sanger, F., Coulson, A. R., Barrell, B. G., Smith, A. J. H. & Roe, B. A. (1980) *J. Mol. Biol.* **143**, 161–178.
- Guo, L. H., Yang, R. C. A. & Wu, R. (1983) *Nucleic Acids Res.* **11**, 5521–5540.
- Eulitz, M. (1974) *Eur. J. Biochem.* **50**, 49–69.
- Kabat, E. A., Wu, T. T., Bilofsky, H., Miller-Reid, M. & Perry, H. (1983) *Sequences of Proteins of Immunological Interest* (Natl. Inst. of Health, Washington, DC).
- Max, E. E., Seidman, J. G. & Leder, P. (1979) *Proc. Natl. Acad. Sci. USA* **76**, 3450–3454.
- Sakano, H., Hüppi, K., Heinrich, G. & Tonegawa, S. (1979) *Nature (London)* **280**, 288–294.
- Early, P., Huang, H., Davis, M., Calame, K. & Hood, L. (1980) *Cell* **19**, 981–992.
- Kojima, M., Odani, S. & Ikenaka, T. (1980) *Mol. Immunol.* **17**, 1407–1414.
- Langer, B., Steinmetz-Kayne, M. & Hilschmann, N. (1968) *Hoppe-Seyler's Z. Physiol. Chem.* **349**, 945–951.
- Titani, K., Wikler, M., Shinoda, T. & Putnam, F. W. (1970) *J. Biol. Chem.* **245**, 2171–2176.
- Shinoda, S., Titani, K. & Putnam, F. W. (1970) *J. Biol. Chem.* **245**, 4475–4487.
- Milstein, C., Clegg, J. B. & Jarvis, J. M. (1968) *Biochem. J.* **110**, 631–652.
- Wikler, M. & Putnam, F. W. (1970) *J. Biol. Chem.* **245**, 4488–4507.
- Garver, F. A. & Hilschmann, N. (1972) *Eur. J. Biochem.* **26**, 10–32.
- Baczko, K., Braun, D. G., Hess, M. & Hilschmann, N. (1970) *Hoppe-Seyler's Z. Physiol. Chem.* **351**, 763–767.
- Scholz, R. & Hilschmann, N. (1975) *Hoppe-Seyler's Z. Physiol. Chem.* **356**, 1333–1335.
- Frangione, B., Moloshok, T. & Solomon, A. (1983) *J. Immunol.* **131**, 2490–2493.
- Ghiso, J., Solomon, A. & Frangione, B. (1986) *J. Immunol.* **136**, 716–719.
- Chen, B. L. & Poljak, R. J. (1974) *Biochemistry* **13**, 1295–1302.
- Engelhard, M., Hess, M. & Hilschmann, N. (1974) *Hoppe-Seyler's Z. Physiol. Chem.* **355**, 85–88.
- Anderson, M. L. M., Brown, L., McKenzie, E., Kellow, J. E. & Young, B. D. (1985) *Nucleic Acids Res.* **13**, 2931–2941.
- Ponstingl, H., Hess, M. & Hilschmann, N. (1971) *Hoppe-Seyler's Z. Physiol. Chem.* **352**, 247–266.
- Garver, F. A., Chang, L., Mendicino, J., Isobe, T. & Osserman, E. F. (1975) *Proc. Natl. Acad. Sci. USA* **72**, 4559–4563.
- Udey, J. A. & Blomberg, B. (1987) *Immunogenetics* **25**, 63–70.